Liproxstatin-1 is primarily used as a potent inhibitor of ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation. It is widely applied in research settings to study the mechanisms and consequences of ferroptosis in various disease models. Its ability to protect cells from oxidative damage makes it valuable in investigating neurodegenerative diseases such as Parkinson’s and Alzheimer’s, where ferroptosis is believed to contribute to neuronal loss. It is also used in studies related to ischemia-reperfusion injury, particularly in the kidney and heart, where it helps reduce tissue damage by preventing lipid peroxidation. In cancer research, Liproxstatin-1 is employed to explore the role of ferroptosis in tumor suppression and therapy resistance, especially in combination with drugs that induce oxidative stress in cancer cells. Due to its cell permeability and stability, it is suitable for both in vitro and in vivo experiments, supporting its use in preclinical models to evaluate therapeutic strategies targeting oxidative cell death pathways.